Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Pancreatic cancer
RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.
Live from ClinicalTrials.gov, fetched 2026-11-12 13:21 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
3%
17 trial titles name relapsed, refractory or recurrent disease
Led by industry
48%
286 trials with a company as lead sponsor
61 of the 600 pancreatic cancer trials are Phase 3; 41 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of pancreatic cancer (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 141 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Advanced or metastatic1L · Locally advanced1L · Neoadjuvant or perioperative2L+2L+ · Adjuvant2L+ · Advanced or metastatic2L+ · Locally advanced2L+ · Maintenance2L+ · Relapsed or refractoryAdjuvantAdvanced or metastaticBRCA · Advanced or metastaticBRCA · Locally advancedKRASKRAS · AdjuvantKRAS · Advanced or metastaticKRAS · Locally advancedKRAS · Relapsed or refractoryKRAS G12CKRAS G12C · Advanced or metastaticKRAS G12DKRAS G12D · 1L · Advanced or metastaticKRAS G12D · 1L · Locally advanced
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| YE-NEO-001 NantBioScience, Inc. | 2L+ · Adjuvant | Other or not recognised | Ph1 | NCT03552718 |
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| nab-paclitaxel | Loma Linda University | |
| Fluorouracil | Northwestern University | |
| Capecitabine | University of Nebraska | |
| Nab paclitaxel | Alliance for Clinical Trials in Oncology | |
| daraxonrasib | Revolution Medicines, Inc. | |
| Atezolizumab | Georgetown University | |
| Navlimetostat | Bristol-Myers Squibb | |
| RMC-6236 | Revolution Medicines, Inc. | |
| Oxaliplatin | Gruppo Oncologico del Nord-Ovest | |
| INCB161734 | Incyte Corporation | |
| surufatinib + gemcitabine + nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | |
| ponsegromab | Pfizer | |
| GFH375 | Genfleet Therapeutics (Shanghai) Inc. | |
| Atebimetinib | Immuneering Corporation | |
| Lanreotide | SWOG Cancer Research Network | |
| Zoldonrasib | Revolution Medicines, Inc. | |
| Setidegrasib | Astellas Pharma Global Development, Inc. | |
| Quemliclustat | Arcus Biosciences, Inc. | |
| Zanzalintinib | Exelixis | |
| Cabozantinib | Exelixis | |
| HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Cabozantinib S-malate | National Cancer Institute (NCI) | |
| HRS-4642 + AG | Jiangsu HengRui Medicine Co., Ltd. | |
| Romiplostim | Amgen | |
| Secretin | Johns Hopkins University | |
| 177Lu-edotreotide PRRT | ITM Solucin GmbH | |
| tabelecleucel | Pierre Fabre Medicament | |
| Paltusotine | Crinetics Pharmaceuticals Inc. | |
| Glufosfamide | Eleison Pharmaceuticals LLC. | |
| RYZ101 | RayzeBio, Inc. |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07900789 HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer Single-country: China (2 sites) Decision brief → | Ph3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | not yet recruiting | 2026-10-28 | 2030-11-30 |
| PREOPANC-4 RCT · NCT07867873 Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy No sites listed Decision brief → | Ph3 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | not yet recruiting | 2026-10-09 | 2034-10-01 |
| NCT07823049 Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy Single-country: China (48 sites) Decision brief → | Ph3 | Evopoint Biosciences Inc. | recruiting | 2026-09-16 | 2027-05-31 |
| RASolute 309 · NCT07805954 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Single-country: United States (6 sites) Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2026-09-08 | 2029-03 |
| NCT07803783 A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Single-country: China (1 site) Decision brief → | Ph3 | MediLink Therapeutics (Suzhou) Co., Ltd. | not yet recruiting | 2026-09-04 | 2029-01 |
| ADGP Ⅱ · NCT07716228 Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound Single-country: China (1 site) Decision brief → | Ph3 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2026-07-21 | 2026-12-06 |
| MATTERS-2 · NCT07711067 A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer 2 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | ElmediX | not yet recruiting | 2026-07-17 | 2030-03-31 |
| NCT07689539 Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation No sites listed Decision brief → | Ph3 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | not yet recruiting | 2026-07-08 | 2028-07 |
| NCT07656376 Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation No sites listed Decision brief → | Ph2/Ph3 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | not yet recruiting | 2026-06-18 | 2029-02-07 |
| NCT07632118 Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery Single-country: China (1 site) Decision brief → | Ph3 | Tianjin Medical University Cancer Institute and Hospital | recruiting | 2026-06-08 | 2029-05 |
| RASolute 305 · NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) 5 countries, 72% of sites in the US Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2026-06-02 | 2028-12-30 |
| NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Single-country: United States (4 sites) Decision brief → | Ph3 | Exelixis | enrolling by invitation | 2026-06-02 | 2030-05-31 |
| ADJUPANET · NCT07591493 Adjuvant Trial in Pancreatic Neuroendocrine Tumors Single-country: France (1 site) Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | not yet recruiting | 2026-05-15 | 2035-06 |
| MAPKeeper 301 · NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma 9 countries, 62% of sites in the US Decision brief → | Ph3 | Immuneering Corporation | recruiting | 2026-05-01 | 2028-06 |
| DAWN-303 · NCT07522073 A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma 22 countries, 30% of sites in the US Decision brief → | Ph3 | Incyte Corporation | recruiting | 2026-04-13 | 2028-09-15 |
| RASolute 303 · NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma 16 countries, 26% of sites in the US Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2026-03-24 | 2028-06 |
| DETERMINE · NCT07440290 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Single-country: United Kingdom (27 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2026-02-27 | 2029-10 |
| NCT07436741 Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph3 | Tianjin Medical University Cancer Institute and Hospital | recruiting | 2026-02-27 | 2028-09 |
| NCT07409272 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer 11 countries, 52% of sites in the US Decision brief → | Ph3 | Astellas Pharma Global Development, Inc. | recruiting | 2026-02-13 | 2029-08-31 |
| NCT07262567 Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph3 | Genfleet Therapeutics (Shanghai) Inc. | recruiting | 2025-12-03 | 2027-06 |
| RASolute 304 · NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) 10 countries, 53% of sites in the US Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2025-11-26 | 2029-05-10 |
| NCT07232875 HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu HengRui Medicine Co., Ltd. | recruiting | 2025-11-18 | 2029-04 |
| NCT07219238 Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) 2 countries, 50% of sites in the US Decision brief → | Ph2/Ph3 | GE Healthcare | recruiting | 2025-10-21 | 2029-06 |
| NCT07138846 A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph3 | Lepu Biopharma Co., Ltd. | not yet recruiting | 2025-08-24 | 2027-06 |
| CAREFNDR · NCT07087054 Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen 14 countries, 24% of sites in the US Decision brief → | Ph3 | Crinetics Pharmaceuticals Inc. | active not recruiting | 2025-07-25 | 2027-08 |
| NCT07081360 Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer Single-country: Egypt (1 site) Decision brief → | Ph3 | Minia University | recruiting | 2025-07-23 | 2028-07-20 |
| NCT07076121 A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) 36 countries, 18% of sites in the US Decision brief → | Ph2/Ph3 | Bristol-Myers Squibb | active not recruiting | 2025-07-21 | 2029-05-03 |
| NCT07066098 A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) Single-country: China (1 site) Decision brief → | Ph3 | Innovent Biologics (Suzhou) Co. Ltd. | recruiting | 2025-07-15 | 2027-06-30 |
| NCT06998940 Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Single-country: United States (274 sites) Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2025-05-31 | 2029-12-31 |
| NCT06989437 A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue 21 countries, 40% of sites in the US Decision brief → | Ph2/Ph3 | Pfizer | recruiting | 2025-05-25 | 2028-01-23 |
| LAP100 · NCT06958328 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | NRG Oncology | recruiting | 2025-05-06 | 2030-10-21 |
| STELLAR-311 · NCT06943755 Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors 18 countries, 30% of sites in the US Decision brief → | Ph2/Ph3 | Exelixis | recruiting | 2025-04-24 | 2029-06-30 |
| PANThEON · NCT06897644 Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. Single-country: Italy (28 sites) Decision brief → | Ph3 | Gruppo Oncologico del Nord-Ovest | recruiting | 2025-03-27 | 2029-01-01 |
| Tumor HI · NCT06881992 A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism 5 countries, 62% of sites in the US Decision brief → | Ph3 | Rezolute | recruiting | 2025-03-18 | 2027-09 |
| NCT06807437 Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula Single-country: United States (118 sites) Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2025-02-04 | 2029-04-01 |
| PLATINUM-CAN · NCT06783140 Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer Single-country: Canada (1 site) Decision brief → | Ph2/Ph3 | University Health Network, Toronto | active not recruiting | 2025-01-20 | 2031-06-02 |
| FAPIDO · NCT06782412 Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types Single-country: Belgium (3 sites) Decision brief → | Ph2/Ph3 | KU Leuven | recruiting | 2025-01-17 | 2027-12 |
| RASolute 302 · NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 7 countries, 62% of sites in the US Decision brief → | Ph3 | Revolution Medicines, Inc. | active not recruiting | 2024-10-03 | 2026-06 |
| PRISM-1 · NCT06608927 Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma 13 countries, 44% of sites in the US Decision brief → | Ph3 | Arcus Biosciences, Inc. | active not recruiting | 2024-09-23 | 2030-11-30 |
| NCT06593431 Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial Single-country: United States (4 sites) Decision brief → | Ph3 | M.D. Anderson Cancer Center | recruiting | 2024-09-19 | 2029-06-29 |
| NCT06361888 A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer Single-country: China (52 sites) Decision brief → | Ph2/Ph3 | Hutchmed | recruiting | 2024-04-12 | 2028-05-31 |
| NCT06115499 The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer Single-country: United States (345 sites) Decision brief → | Ph2/Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2023-11-03 | 2027-12-01 |
| NCT06091748 Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu HengRui Medicine Co., Ltd. | completed | 2023-10-19 | 2025-11-27 |
| NCT05884255 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Single-country: China (2 sites) Decision brief → | Ph3 | Jiangsu HengRui Medicine Co., Ltd. | recruiting | 2023-06-01 | 2026-12 |
| NCT05840341 Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer Single-country: China (4 sites) Decision brief → | Ph3 | Fudan University | completed | 2023-05-03 | 2025-12-30 |
| NCT05836870 Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph3 | M.D. Anderson Cancer Center | active not recruiting | 2023-05-01 | 2030-12-31 |
| NCT05720338 Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? Single-country: United States (1 site) Decision brief → | Ph3 | Case Comprehensive Cancer Center | recruiting | 2023-02-09 | 2026-12-31 |
| MRD-GI · NCT05482516 Evaluating Novel Therapies in ctDNA Positive GI Cancers Single-country: United States (1 site) Decision brief → | Ph3 | Georgetown University | active not recruiting | 2022-08-01 | 2026-08-20 |
| ACTION-1 · NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy 8 countries, 59% of sites in the US Decision brief → | Ph3 | RayzeBio, Inc. | active not recruiting | 2022-07-28 | 2026-12 |
| NCT04931394 Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph3 | Changhai Hospital | completed | 2021-06-18 | 2024-05-31 |
| PREOPANC-3 · NCT04927780 Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer 2 countries, 0% of sites in the US Decision brief → | Ph3 | Erasmus Medical Center | active not recruiting | 2021-06-16 | 2027-01 |
| NCT04340141 Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer 2 countries, 97% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2020-04-09 | 2028-12-31 |
| ALLELE · NCT03394365 A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy 9 countries, 56% of sites in the US Decision brief → | Ph3 | Pierre Fabre Medicament | recruiting | 2018-01-09 | 2030-05-31 |
| NCT03375320 Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Single-country: United States (432 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2017-12-18 | 2023-08-23 |
| RECITE · NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer 20 countries, 19% of sites in the US Decision brief → | Ph3 | Amgen | completed | 2017-12-05 | 2024-01-25 |
| TIGeR-PaC · NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC 2 countries, 84% of sites in the US Decision brief → | Ph3 | RenovoRx | active not recruiting | 2017-08-22 | 2027-06 |
| COMPETE · NCT03049189 Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients 14 countries, 12% of sites in the US Decision brief → | Ph3 | ITM Solucin GmbH | active not recruiting | 2017-02-09 | 2024-11-27 |
| CAPS5 · NCT02000089 The Cancer of the Pancreas Screening-5 CAPS5)Study Single-country: United States (9 sites) Decision brief → | Ph3 | Johns Hopkins University | recruiting | 2013-12-03 | 2028-12 |
| NCT01954992 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Single-country: United States (3 sites) Decision brief → | Ph3 | Eleison Pharmaceuticals LLC. | recruiting | 2013-10-07 | 2028-03 |
| NCT01744249 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas 4 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Grupo Espanol de Tumores Neuroendocrinos | completed | 2012-12-06 | 2023-12-31 |
| NCT00974948 Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis Single-country: Canada (1 site) Decision brief → | Ph3 | Centre hospitalier de l'Université de Montréal (CHUM) | completed | 2009-09-11 | 2008-12 |
| NCT07920731 A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | enrolling by invitation | 2026-11-06 | 2028-08-10 |
| NCT07912593 Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Ensem Therapeutics | recruiting | 2026-11-03 | 2028-10-30 |
| M-POP · NCT07905131 A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Daniel Nussbaum, M.D. | not yet recruiting | 2026-10-29 | 2029-06-30 |
| NCT07897734 TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients No sites listed Decision brief → | Ph1/Ph2 | Tango Therapeutics, Inc. | not yet recruiting | 2026-10-27 | 2031-11 |
| NCT07897227 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. No sites listed Decision brief → | Ph1/Ph2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | not yet recruiting | 2026-10-27 | 2029-05-01 |
| NCT07895498 A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-10-26 | 2028-10-16 |
| ILDR-ICI-LM · NCT07875465 Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases Single-country: China (1 site) Decision brief → | Ph2 | Bing Xia | not yet recruiting | 2026-10-15 | 2029-04 |
| NCT07871461 Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | not yet recruiting | 2026-10-13 | 2027-09 |
| NCT07864571 Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Jun Gong, MD | not yet recruiting | 2026-10-08 | 2028-12 |
| LEN-pNET · NCT07835893 Lenvatinib Plus Chemotherapy for pNET Liver Metastases Single-country: China (1 site) Decision brief → | Ph2 | Peking Union Medical College Hospital | recruiting | 2026-09-23 | 2028-04-01 |
| ZSPAC-22 · NCT07833241 Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Single-country: China (1 site) Decision brief → | Ph2 | Shanghai Zhongshan Hospital | not yet recruiting | 2026-09-22 | 2028-09-01 |
| NCT07831330 Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer No sites listed Decision brief → | Ph2 | The First Affiliated Hospital with Nanjing Medical University | not yet recruiting | 2026-09-21 | 2029-01-31 |
| NCT07828756 Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | not yet recruiting | 2026-09-18 | 2027-10-31 |
| NCT07827053 Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer No sites listed Decision brief → | Ph2 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | not yet recruiting | 2026-09-18 | 2029-09-01 |
| PROBE · NCT07825753 Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | not yet recruiting | 2026-09-17 | 2027-09-01 |
| Panc 004 · NCT07824960 Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Virginia | not yet recruiting | 2026-09-17 | 2029-04 |
| NCT07814859 Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Zhengzhou University | not yet recruiting | 2026-09-11 | 2027-08-31 |
| NCT07814066 A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer No sites listed Decision brief → | Ph2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | not yet recruiting | 2026-09-10 | 2028-02-28 |
| NCT07806058 An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Jiangsu HengRui Medicine Co., Ltd. | recruiting | 2026-09-08 | 2028-12-31 |
| NCT07806110 Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | The First Hospital of Jilin University | active not recruiting | 2026-09-08 | 2027-12-31 |
| NCT07802184 GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC Single-country: China (1 site) Decision brief → | Ph1/Ph2 | West China Hospital | recruiting | 2026-09-03 | 2029-01-01 |
| TAILOR-PANC · NCT07802418 Molecularly Tailored Therapy in Advanced Pancreatic Cancer Single-country: Denmark (4 sites) Decision brief → | Ph2 | Herlev Hospital | not yet recruiting | 2026-09-03 | 2031-06 |
| NCT07784374 A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation Single-country: China (1 site) Decision brief → | Ph2 | Genfleet Therapeutics (Shanghai) Inc. | recruiting | 2026-08-25 | 2028-08-31 |
| NCT07777211 A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Gene Key Life Technology Co., Ltd | recruiting | 2026-08-20 | 2027-03-31 |
| NCT07773363 Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer No sites listed Decision brief → | Ph2 | Tang-Du Hospital | not yet recruiting | 2026-08-19 | 2027-12-30 |
| NCT07769502 A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers 4 countries, 14% of sites in the US Decision brief → | Ph2 | AbbVie | recruiting | 2026-08-18 | 2028-09 |
| EKLAVYA-HRD · NCT07765836 Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC Single-country: United States (1 site) Decision brief → | Ph2 | Massachusetts General Hospital | not yet recruiting | 2026-08-14 | 2028-12-31 |
| NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation No sites listed Decision brief → | Ph1/Ph2 | LG Chem | not yet recruiting | 2026-08-07 | 2032-10-31 |
| NCT07748611 SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Single-country: United States (1 site) Decision brief → | Ph2 | Northwestern University | recruiting | 2026-08-06 | 2030-02-03 |
| NCT07745790 Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | Ruijin Hospital | not yet recruiting | 2026-08-04 | 2029-07-31 |
| NCT07736612 A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Zhejiang University | not yet recruiting | 2026-07-30 | 2028-08-30 |
| NCT07705919 DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Ohio State University Comprehensive Cancer Center | recruiting | 2026-07-15 | 2027-12-31 |
| FAPIPET · NCT07705074 FAPI PET Imaging - An Exploratory Study Single-country: Switzerland (5 sites) Decision brief → | Ph1/Ph2 | Martin Huellner | not yet recruiting | 2026-07-15 | 2029-09 |
| VIRAGE2 · NCT07701486 A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer Single-country: Spain (1 site) Decision brief → | Ph1/Ph2 | Theriva Biologics SL | recruiting | 2026-07-14 | 2027-08-01 |
| NCT07702292 [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications 2 countries, 0% of sites in the US Decision brief → | Ph2 | Blue Earth Diagnostics | recruiting | 2026-07-14 | 2028-02 |
| NCT07698613 EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Brown University | not yet recruiting | 2026-07-13 | 2029-03 |
| NCT07692750 IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Zhejiang Cancer Hospital | recruiting | 2026-07-09 | 2027-06-30 |
| NCT07691593 Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer No sites listed Decision brief → | Ph2 | Changhai Hospital | not yet recruiting | 2026-07-09 | 2027-10 |
| PANCPLEX · NCT07689955 A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer No sites listed Decision brief → | Ph2 | Royal Marsden NHS Foundation Trust | not yet recruiting | 2026-07-08 | 2029-09 |
| NCT07683221 SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | Shandong Cancer Hospital and Institute | recruiting | 2026-07-06 | 2029-07-15 |
| NCT07678593 A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation 2 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Genfleet Therapeutics (Shanghai) Inc. | recruiting | 2026-07-01 | 2027-11 |
| NCT07670312 Evaluation of XYA02 in Patients With Advanced Solid Tumors Single-country: Australia (5 sites) Decision brief → | Ph1/Ph2 | XYone Therapeutics, Inc | recruiting | 2026-06-26 | 2029-09-15 |
| SONIC · NCT07665684 Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer Single-country: Canada (1 site) Decision brief → | Ph1/Ph2 | University Health Network, Toronto | not yet recruiting | 2026-06-24 | 2029-05 |
| NCT07644559 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer 4 countries, 71% of sites in the US Decision brief → | Ph2 | Verastem, Inc. | recruiting | 2026-06-12 | 2027-06 |
| NCT07640295 Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations Single-country: China (13 sites) Decision brief → | Ph1/Ph2 | Jacobio Pharmaceuticals Co., Ltd. | recruiting | 2026-06-10 | 2029-12-31 |
| NCT07631884 Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor No sites listed Decision brief → | Ph2 | Haihua Yuan | not yet recruiting | 2026-06-08 | 2028-12-31 |
| NCT07631871 An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy No sites listed Decision brief → | Ph2 | Haihua Yuan | not yet recruiting | 2026-06-08 | 2029-12-31 |
| NCT07629960 A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations 2 countries, 63% of sites in the US Decision brief → | Ph1/Ph2 | Blueprint Medicines Corporation | recruiting | 2026-06-05 | 2029-09 |
| BEFAST · NCT07629609 BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer Single-country: Denmark (1 site) Decision brief → | Ph2 | Barbara Malene Fischer | recruiting | 2026-06-05 | 2027-01 |
| DUAL-NK-PDAC · NCT07627711 Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Biotech | recruiting | 2026-06-04 | 2027-04-14 |
| NCT07623642 A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. Single-country: China (2 sites) Decision brief → | Ph2 | GV20 Therapeutics | not yet recruiting | 2026-06-03 | 2028-06-15 |
| NCT07619521 Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | recruiting | 2026-06-02 | 2028-09-08 |
| NCT07610798 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Ionova Life Sciences Co., Ltd. | recruiting | 2026-05-28 | 2029-05 |
| NCT07600268 Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | Shandong Cancer Hospital and Institute | recruiting | 2026-05-20 | 2028-08-14 |
| NCT07594626 BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Northwestern University | recruiting | 2026-05-19 | 2030-12-09 |
| PANCOSIL · NCT07595835 CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer Single-country: Netherlands (1 site) Decision brief → | Ph1/Ph2 | M.R. Meijerink | recruiting | 2026-05-19 | 2026-06-01 |
| NCT07595172 NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph1/Ph2 | West China Hospital | recruiting | 2026-05-19 | 2028-08 |
| NCT07589569 An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer Single-country: China (2 sites) Decision brief → | Ph2 | Shandong Suncadia Medicine Co., Ltd. | recruiting | 2026-05-15 | 2028-12 |
| N01-A-PICIT-GI · NCT07586813 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Single-country: China (1 site) Decision brief → | Ph2 | Peking University People's Hospital | recruiting | 2026-05-14 | 2027-10-31 |
| NUMANTIA-2 · NCT07578337 A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. Single-country: Spain (6 sites) Decision brief → | Ph2 | Nelum Corp | not yet recruiting | 2026-05-11 | 2029-02-28 |
| NCT07575191 Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer Single-country: Sweden (1 site) Decision brief → | Ph1/Ph2 | Smartwise Sweden AB | recruiting | 2026-05-08 | 2027-12 |
| TEADCO · NCT07563738 A 2-part Phase 1/2 Open-label Trial on ODM-212 7 countries, 22% of sites in the US Decision brief → | Ph1/Ph2 | Orion Corporation, Orion Pharma | recruiting | 2026-05-04 | 2029-09 |
| NCT07561463 Sacituzumab Tirumotecan for Pancreatic Cancer No sites listed Decision brief → | Ph2 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | not yet recruiting | 2026-05-01 | 2027-01-01 |
| NCT07539155 Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Arkansas | recruiting | 2026-04-20 | 2028-08 |
| NCT07529808 Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | BigHat Biosciences, Inc. | recruiting | 2026-04-14 | 2028-12 |
| ERASE-Chemo · NCT07529483 Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Single-country: United States (1 site) Decision brief → | Ph2 | Ohio State University Comprehensive Cancer Center | recruiting | 2026-04-14 | 2027-12-31 |
| NCT07492680 A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) 13 countries, 28% of sites in the US Decision brief → | Ph2 | Bristol-Myers Squibb | recruiting | 2026-03-25 | 2028-08-15 |
| NCT07488676 A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors 2 countries, 86% of sites in the US Decision brief → | Ph1/Ph2 | Astellas Pharma Global Development, Inc. | recruiting | 2026-03-23 | 2029-07-31 |
| UNLOCK ASP3082 · NCT07483983 Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance Single-country: France (7 sites) Decision brief → | Ph2 | Gustave Roussy, Cancer Campus, Grand Paris | recruiting | 2026-03-19 | 2027-09 |
| NCT07483554 IBI343 in Combination Therapy for Advanced Malignant Solid Tumors Single-country: China (1 site) Decision brief → | Ph2 | Innovent Biologics (Suzhou) Co. Ltd. | recruiting | 2026-03-19 | 2028-03-31 |
| FAPDIG · NCT07478523 FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers Single-country: France (1 site) Decision brief → | Ph2 | University Hospital, Bordeaux | recruiting | 2026-03-17 | 2028-03-21 |
| NCT07450859 A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 2 countries, 75% of sites in the US Decision brief → | Ph2 | BicycleTx Limited | recruiting | 2026-03-05 | 2029-03 |
| NCT07444541 ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Anova Innovation Limited | recruiting | 2026-03-03 | 2027-08 |
| NCT07435038 Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS 2 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Betta Pharmaceuticals Co., Ltd. | recruiting | 2026-02-27 | 2028-12-28 |
| NCT07438106 A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital with Nanjing Medical University | recruiting | 2026-02-27 | 2027-10 |
| NCT07432633 [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Blue Earth Diagnostics | recruiting | 2026-02-25 | 2028-01-31 |
| NCT07377526 TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | suspended | 2026-01-30 | 2028-03-01 |
| AxeCan · NCT07354919 Axelopran for Advanced Cancer in Patients Receiving Opioids Single-country: United States (2 sites) Decision brief → | Ph2 | HealthPartners Institute | recruiting | 2026-01-21 | 2027-11-01 |
| DZ-002-201 · NCT07344220 Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate Single-country: United States (1 site) Decision brief → | Ph2 | Hoag Memorial Hospital Presbyterian | enrolling by invitation | 2026-01-15 | 2028-11 |
| NCT07341737 SL-28 for Advanced Solid Tumours Single-country: Australia (3 sites) Decision brief → | Ph1/Ph2 | Second Life Therapeutics | recruiting | 2026-01-14 | 2027-01-01 |
| NCT07283705 A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-12-16 | 2029-10-01 |
| NCT07285044 The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Single-country: United States (1 site) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-12-16 | 2027-05-15 |
| OLIGOMETS · NCT07282912 Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Single-country: United States (1 site) Decision brief → | Ph2 | Yale University | recruiting | 2025-12-15 | 2028-06 |
| GOBLET · NCT07280377 A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Single-country: Germany (15 sites) Decision brief → | Ph1/Ph2 | Oncolytics Biotech | active not recruiting | 2025-12-12 | 2027-07-30 |
| NCT07259317 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Single-country: United States (20 sites) Decision brief → | Ph2 | Corcept Therapeutics | recruiting | 2025-12-02 | 2027-09 |
| NCT07255404 A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer 2 countries, 0% of sites in the US Decision brief → | Ph2 | BioNTech SE | recruiting | 2025-12-01 | 2027-12 |
| NCT07226856 BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Single-country: United States (3 sites) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-11-12 | 2027-02-28 |
| NCT07223047 A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies 3 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Bristol-Myers Squibb | recruiting | 2025-10-31 | 2028-10-13 |
| NCT07214298 Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Roswell Park Cancer Institute | recruiting | 2025-10-09 | 2028-02-16 |